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Abstract
Background: In South Africa in 2010, about 340,000 children under the age of 15 were infected with HIV. We describe the
increase in the treatment of South African pediatric HIV-infected patients assisted by the President’s Emergency Plan for
AIDS Relief (PEPFAR) from 2004 to 2010.
Methods: We reviewed routine program data from PEPFAR-funded implementing partners among persons receiving
antiretroviral treatment age 15 years old and less. Data quality was assessed during the reporting period by program
officials through routine analysis of trends and logic checks. Based on UNAIDS estimated mortality rates of untreated HIV-
infected children, we calculated the number of deaths averted and life-years gained in children under five receiving PEPFAR-
assisted antiretroviral treatment.
Results: From October 2004 through September 2010, the number of children newly initiated on antiretroviral treatment in
PEPFAR-assisted programs increased from 154 to 2,641 per month resulting in an increase from 2,412 children on
antiretroviral treatment in September 2005 to 79,416 children in September 2010. Of those children who initiated
antiretroviral treatment before September 2009, 0–4 year olds were 1.4 (95% CI: 1.3–1.5) times as likely to transfer out of the
program or die as 5–14 year olds; males were 1.3 (95% CI: 1.0–1.7) times as likely to stop treatment as females.
Approximately 27,548 years of life were added to children under-five years old from PEPFAR-assisted antiretroviral
treatment.
Conclusions: Pediatric antiretroviral treatment in South Africa has increased substantially. However, additional case-finding
and a further acceleration in the implementation of pediatric care and treatment services is required to meet the current
treatment need.
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Introduction
South Africa has the world’s greatest burden of Human
Immunodeficiency Virus (HIV) infection with an estimated 5.7
million persons infected with HIV in 2010, including 340,000
children under the age of 15 years [1,2]. South Africa’s under five
mortality rate increased substantially from 1996–2001 [3]. Most of
those deaths are caused by conditions that are either preventable
or treatable, such as Acquired Immune Deficiency Syndrome
(AIDS) (35%), neonatal causes (30%) and pneumonia and diarrhea
(17%) [4]. The South African Government (SAG) launched a
national strategy to address the HIV epidemic in children and
adults in 2003 [5]. The SAG Guidelines for the Management of
HIV in Children at that time (in 2004) outlined criteria for
commencing antiretroviral therapy (ART) as CD4 percentage
,20% in a child under 18 months old and CD4 percentage
,15% in a child over 18 months old [6]. In April 2010 those
criteria were expanded to include ART for all HIV-infected
infants, children 1–5 years old with CD4 T-cell counts ,750 cells/
mm3 and 5–15 years olds with CD4 T-cell counts ,350 cells/
mm3.
In 2004 the United States President’s Emergency Plan for AIDS
Relief (PEPFAR) began assisting the SAG to establish and scale up
HIV prevention, care and treatment programs in private, non-
government and government-supported clinics through partner-
ships with various implementing organizations [7]. PEPFAR
assists the delivery of antiretroviral treatment (ART) through a
range of services depending on the resource needs of the facility.
Assistance may include the renovation of facilities, hiring of
clinical staff, training and mentoring of clinicians, technical
expertise, laboratory services, supply chain strengthening, the
provision and distribution of drugs, quality assurance, and
monitoring and evaluation activities. Approximately 90% of
PEPFAR assistance goes toward government facilities with the
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remaining 10% reaching private facilities. The South African
National Department of Health is responsible for policy develop-
ment and implementation including determination of the eligibil-
ity criteria for treatment initiation. Over the period 2004–2010 the
National Department of Health took increasing responsibility for
procurement of prophylactic and antiretroviral drugs, reimburse-
ment for the laboratory costs, and supply of the professional
workforce.
In 2005, of the approximately 93,000 children in need of ART,
less than 12,000 (13%) were receiving treatment [2,8]. In 2010,
183,000 South African children were estimated to require ART
[2]. The SAG set targets to initiate 38,000 new children on ART
between April 2010 and March 2011, and have 150,134 children
on ART by March 2011 [9].
Using routine program data, we describe increases in pediatric
HIV/AIDS treatment and select outcomes in PEPFAR-assisted
programs in South Africa from 2004 through 2010.
Patients and Methods
We reviewed routine quarterly HIV care and treatment
program output data submitted by PEPFAR-funded implementing
partners, primarily local and international non-governmental
organizations who are responsible for the delivery of high-quality
HIV care and treatment programs. Those partners submit
quarterly data through an open-source web-based platform.
Partners reported by healthcare facility the following measures:
the number of patients initiating (newly initiated and those
transferred in) ART, currently receiving ART, and the cumulative
number not receiving ART by age group. Those not receiving
ART were defined as those who were seen at a clinic but did not
meet eligibility criteria for ART; or had been on ART and
categorized as discontinued due to lost-to-follow-up, transferred
out, stopped, died or unknown reasons. Data were reviewed for
face-validity, trends and logical errors for each submitting partner
each quarter by program officials during the reporting period. We
could only access data from pediatric HIV programs that were
partially or fully supported by PEPFAR. Therefore, we did not
include pediatric HIV-infected patients who were cared for by
private practitioners or SAG programs not associated with
PEPFAR. To assess the reach of the PEPFAR program, we
obtained the number of children on ART nationwide from the
National Department of Health ART monitoring and evaluation
system (a paper-based monthly reporting system) [8].
We completed a retrospective analysis of measures for persons
less than 15 years old who ever received ART in PEPFAR-assisted
programs in South Africa between October 1, 2004 and
September 30, 2010. Detailed data on attrition were only available
from April 1, 2008 through September 30, 2009. Using Microsoft
ExcelH and SASH version 9.1 (SAS Institute Inc., Cary, NC), data
were analyzed at the end of each of the United States Government
fiscal year (October 1-September 30). We calculated monthly
averages by dividing the total number for a period by the number
of months in that period. We calculated prevalence ratios (PR) and
95% confidence intervals (CI) by age group and continuation on
antiretroviral therapy. We estimated the number of years of life
added due to treatment of HIV-infected 0–4 year olds, up to 30
years of age. To do that, we used the number of children currently
on ART at the end of our study period. Mortality estimates for
children on ART and children not on ART were derived from
UNAIDS/UNICEF recommendations and other published re-
views included in Spectrum Software version 4.351 [10]. We used
those estimates to calculate the combined number of years the
children would have lived if they were not provided with ART and
subtracted it from the number of years those children were
expected to live now that they are on ART. To simplify the model
the mortality estimates for children not on ART assume only
perinatal infection. The mortality estimates account for varying
mortality risk in each year of life. We also calculated the number of
deaths averted in the first five years of life for the 0–4 year olds
currently on PEPFAR-assisted ART at the end of the study period
by subtracting the number of deaths estimated for children on
ART from those not on ART using mortality estimates from
Spectrum [10].
In accordance with United States regulations and international
guidelines, the Centers for Disease Control and Prevention and
the South African Government determined the review of
programmatic data and subsequent analyses to be a non-research
activity.
Results
The number of children ever initiated on PEPFAR-assisted
ART increased from 2,412 children in September 2005 to 79,416
children in September 2010, a 32-fold increase (Figure 1). The
rapid increase of ART within PEPFAR-assisted programs
contributed substantially to expanding coverage from the estimat-
ed 12.5% of HIV-infected children in need of ART in 2005 to
over 54% in September 2010. As part of the national effort,
PEPFAR-assisted programs contributed to 20% of children
receiving ART in 2005 and to over 75% of those receiving
treatment in September 2009 (Figure 2).
The number of children in PEPFAR-assisted programs newly
initiating ART per month increased 16-fold from 154 new
children per month in 2005 to 2,641 new children per month in
2010 (Figure 3). From March to June 2010, 9,107 children were
newly initiated on ART by PEPFAR-assisted programs contrib-
uting to 24% of the March 2011 SAG target.
Of the 74,549 children started on ART, 66,870 (89.7%) were
retained on ART by the end of September 2009. The attrition of
7,679 children from ART in PEPFAR-assisted program between
April 2008 and September 2009 can be attributed to multiple
causes: of the 74,549 children who ever initiated ART, 0.3% had
stopped treatment (0.28% of 0–4 year olds compared to 0.34% of
5–14 year olds (PR = 0.83, CI 0.63–1.09)), 4.0% had transferred
care (5.0% of 0–4 year olds compared to 3.5% of 5–14 year olds
(PR = 1.41, CI 1.32–1.52)), 1.3% had died (1.6% of 0–4 year olds
compared to 1.2% of 5–14 year olds (PR = 1.32, CI 1.17–1.50)),
and 4.6% were lost to follow-up (4.8% of 0–4 year olds compared
to 4.6% of 5–14 year olds (PR = 1.05, CI 0.98–1.12)), (Figure 4).
Males were 1.35 times as likely as females to stop treatment (CI
1.04–1.74).
Just over one-third of the 79,416 HIV-infected children on
PEPFAR-assisted ART in South Africa is younger than five years
old. After removing an additional 8.9% for children who were lost-
to-follow-up, transferred, or stopped treatment, a total of 23,875
children remain for analysis. Those children would live for a total
of 59,830 years without treatment and 87,378 years with
treatment. This suggests that ART has added 27,548 years of
life for children under five who were receiving ART in September
2010. Alternatively, in the first five years of life it is estimated that
13,875 of these children would die without treatment as opposed
to 8,046 on treatment, suggesting that in the first five years of life,
ART averted 5,829 deaths.
Discussion
The provision of ART to children in South Africa has greatly
increased in the past six years through the South African
Increased Pediatric Treatment, South Africa
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government’s treatment programs and with the assistance of
PEPFAR. The 79,416 children currently receiving PEPFAR-
assisted ART in September 2010 contribute to over 50% of the
March 2011 SAG target of 150,134 children receiving ART. In
April 2010, the SAG updated the criteria for ART initiation to: all
HIV-infected infants ,1 year old, 1–5years olds with CD4 T cell
counts ,750 cells/mm3 and 5–15 year olds with CD4 T cell
counts ,350 cells/mm3 to help prevent high mortality in
untreated children [11,12]. As those guidelines are put into effect,
the number of children receiving ART should further increase
substantially [13].
Pediatric treatment services are largely centralized (based at
district hospitals) at present. In 2006, only 6% of children received
ART in community (or primary) health centers in the most
populated province, Gauteng [14]. However, it has been shown
that provision of ART at the primary healthcare clinic level can
result in increased number of patients receiving therapy without
compromising quality of care [15]. In April 2010, the SAG
prioritized Nurse Initiated and Managed Antiretroviral Treatment
(NIMART) to decentralize adult services. The addition of
pediatric care and treatment components to the NIMART
program could further increase the number of children provided
with ART.
Similar to other studies in which an administrative database was
used, our study had some limitations. Programmatic measures
change frequently, undergo inconsistent quality assurance, and are
subject to over- and under-reporting. Due to programmatic
changes in data collection procedures, data related to pediatric
mortality and treatment drop-out were available for only six of the
24 quarters in the study period, and therefore, might not be
generalizable. Additionally, the comparisons of outcomes between
children age less than 5 years of age and greater than 5 years of
age must be interpreted with caution since those on treatment age
greater than 5 years of age have a survival bias. The characteristics
of survivors might be different than non-survivors. Regardless, the
main findings are likely valid and are consistent with past studies
that also showed that loss to follow-up in this population secondary
to transfer of care to other treatment providers is an issue, thus
necessitating additional efforts to understand why 0–4 year olds
are more likely to transfer care or die [21]. Other measures, such
as the age of ART initiation, provider type, regimen type and
duration, serial CD4 T-cell counts, plasma HIV viral load,
hospitalization and mortality, should be routinely collected among
the pediatric population in order to discern any differences in
clinical outcomes at the national level.
The proportion of children continuing on treatment (89.7%)
was better than that of the adult population (77%) in PEPFAR-
assisted programs in South Africa for a similar period [16] and on
the higher end of other reports on children from sub-Saharan
Africa [17–19]. Because cumulative attrition data were reported
Figure 1. Initiation and Continuation of PEPFAR-assisted Antiretroviral Treatment (ART) in Children, South Africa, 2005–2010.
doi:10.1371/journal.pone.0044914.g001
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each quarter, there may have been some misclassification of
program outcomes due to reporting error. We were limited by the
available data in determining factors that might influence
retention. Detailed patient data such as, clinical stage of illness,
socioeconomic status, migration status and health of primary
caregiver along with facility characteristics such as, the size of the
facility, ratio of staff-to-patients, urban versus rural setting,
transport costs, and average distance from patient’s homes were
not available. Further evaluation is needed to understand how
those characteristics might contribute to difference in continuation
on ART in children.
While the overall reported discontinuation of PEPFAR-assisted
treatment was relatively low, the most frequent reason (4.6%) was
lost to follow-up, followed by transferred care (4.0%). Current
Figure 2. Percent Contribution to Antiretroviral Treatment (ART) Need in Children by PEPFAR Assistance, South Africa 2005–2009.
doi:10.1371/journal.pone.0044914.g002
Figure 3. Average Number of Newly Initiated Children per Month in PEPFAR-assisted Antiretroviral Therapy (ART) Programs by
year, South Africa, 2005–2010.
doi:10.1371/journal.pone.0044914.g003
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patient monitoring systems for HIV care and treatment in South
Africa are unevenly distributed across clinical sites and do not
allow for the tracking of individuals at the provincial or national
level [20]. A national system utilizing a unique patient identifier
could greatly facilitate the care of patients and the monitoring of
patient outcomes. However, the system must be designed to ensure
patient confidentiality. Furthermore, patient outcomes can be
improved by supporting current efforts to initiate an HIV case
reporting system.
When estimating number of years of life added for children
under five, we only took into account ART administration. Our
estimate is conservative in that we did not take into account the
impact of pre-ART care interventions, such as nutritional
programs and opportunistic infection prophylaxis, which may
also lead to reduced mortality [21–22]. However, our assumptions
did include perinatal transmission for those children not receiving
treatment, which is the worst-case scenario and may overestimate
mortality. As interventions to prevent mother to child transmission
improve, there will be fewer perinatal infections. We also assumed
that children on ART began early in life, which may overestimate
the number of life-years added by treatment. South African vital
statistics demonstrate a trend in declining all-cause mortality in
children under five beginning in 2006, after a steady and dramatic
increase in mortality from 2001–2006, further supporting the link
between ART and reduced mortality [3,23].
Initiatives to prevent and treat HIV infection are underway in
South Africa; however, HIV/AIDS cannot be looked at in
isolation without addressing other factors contributing to the
increased infant/child mortality, such as infant and child feeding
practices and respiratory diseases. The functional separation of
services such as Prevention of Mother to Child Transmission
programs, immunizations, management of childhood illnesses, and
diagnosis of HIV infection leads to decreased continuity of care for
children and missed opportunities for intervention resulting in
increased morbidity and mortality. Integration of services and
increased involvement of community health workers could
enhance the probability of achieving national goals [14].
Community health workers help HIV infected patients initiate
care at earlier stages and they improve patient retention, especially
in rural settings [15]. Also, programs to improve family planning
and maternal health are necessary for long-term success with
children as the prevalence of HIV infection in child-bearing
women is 29% [24] and it is clear that disability and loss of
mothers (due to morbidity or mortality) affects the overall welfare
of the child.
From 2005–2010, the SAG with assistance from PEPFAR
increased ART for children. This collaboration added approxi-
mately 27,549 years of life for under-five children currently
receiving ART. While that is a major medical achievement,
significant challenges lay ahead in terms of reaching the national
targets and providing life-long care and treatment. Specific needs
to address are: lack of a central system for case reporting, reliable
distribution of antiviral and other life-saving drugs to all clinics,
decentralization of ART initiation and administration, integrated
care, and strengthening the capacity of community-based services.
At present, the management of HIV infection necessitates lifelong
regular clinical care. Capacitating the South African public
medical system and providing care and treatment for HIV-
infected children will require increased local community involve-
ment, advocacy, financial investment and political will.
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